GEN-MKT-18-7897-A
Aug 7, 2019 | Blogs, Pharma | 0 comments
Wouldn’t it be great if we really could “get time back” or even “buy time”? When developing pharmaceuticals, it takes years to bring a new therapy to the market due to the linear nature of the process. As the saying goes, “Time waits for no one.” But what if we could do more in the same period, effectively slowing time down? Then we would be in the favorable situation of having time on our hands.
In pharmaceutical development, many new compounds are screened for their effectiveness during the discovery process. The efficacy is determined by various tests to ensure that the compounds are effective and safe. Many analytical technologies, all with different capabilities, are employed to screen the vast numbers of compounds and deliver an analytical determination. Let’s take high-throughput screening (HTS) assays in pharmaceutical development as an example. Have you ever considered that these are potential bottlenecks to sample throughput today? Have you ever thought that the effort it takes to develop and validate an assay is overly time-consuming? Or been concerned that the results from HTS assays have high numbers of false positives/negatives that mean you spend even more time on data evaluation? Then mass spectrometry (MS) based systems could be the way to improve the selectivity of results, gain confidence in the data, and provide the ability to multiplex—allowing you to do more on a single system. But MS-based technology has its pitfalls, too. One potential bottleneck, particularly with MS-based detection, is that it often requires the use of liquid chromatographic (LC) separation to help with the removal of chemical and matrix-related interferences. This enhances compound ionization and thus selective detection, but adds time to the analysis. Up until today, some of the quickest analysis times with MS have been in the region of 1 sample every 15 seconds.
So, have you heard about Acoustic Ejection Mass Spectrometry technology (AEMS) recently introduced at ASMS 2019 by SCIEX? This technology has the potential to surpass the limits of sample analysis throughput and revolutionize HTS in both speed, accuracy, and precision. With the Echo MS system, the speed of analysis can be as fast as 3 samples per second—50 times faster than current MS-based assays. Your current and future high-throughput screening workflows can be transformed with this new frontier in contactless sampling. The Echo MS system combines the pioneering innovations of an Open Port Interface (OPI) and Acoustic Droplet Ejection (ADE) to form an Acoustic Ejection Mass Spectrometry system. Powerful but gentle in its approach, ADE technology is built into a liquid handler. It focuses ultrasonic acoustic energy at the meniscus of a fluid sample to eject small droplets of liquid (between 1 and 10 nL) from microtiter plates wells (96, 384 or 1536) into the OPI. That is where the very accurate droplets are transferred to a SCIEX mass spectrometer ion source for detection using mass analysis. This results in answers at speeds of up to 180 samples/min, or about 260,000 per day. The accuracy and precision of the assays benefit from the capability of mass spectrometry analysis to deliver <5% CV, along with high levels of uptime because of the use of the OPI in combination with the proprietary SCIEX OptiFlow® Turbo V source. Other key benefits include:
Not convinced? Learn More >
Register your interest in AEMS and gain insight into the potential of this new technology over the coming months.
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Posted by
You must be logged in to post a comment.
Share this post with your network